Digital Library
Close Browse articles from a journal
     Journal description
       All volumes of the corresponding journal
         All issues of the corresponding volume
                                       All articles of the corresponding issues
 
                             27 results found
no title author magazine year volume issue page(s) type
1 Biomarkers for Alzheimer’s disease trials — biomarkers for what? A discussion paper Lovestone, S.
2009
13 4 p. 334-336
article
2 Biomarkers in clinical trials of Alzheimer Disease (AD): What is expected from regulatory agencies? Sampaio, C.
2009
13 4 p. 339-340
article
3 Challenges in the conduct of disease-modifying trials in ad: Practical experience from a phase 2 trial of TAU-aggregation inhibitor therapy Wischik, C.
2009
13 4 p. 367-369
article
4 Defining frailty — the holy grail of geriatric medicine Conroy, S.
2009
13 4 p. 389
article
5 Enrichment of MCI and early Alzheimer’s disease treatment trials using neurochemical & imaging candidate biomarkers Hampel, H.
2009
13 4 p. 373-375
article
6 Frailty: Defining and measuring of a concept Pel-Littel, R. E.
2009
13 4 p. 390-394
article
7 Gerontology and geriatrics, a worldwide expansion in 2009: Data from the IAGG World Meeting Paris 2009, July 5–9th Vellas, B.
2009
13 4 p. 292
article
8 How can we recognize “disease modification” effects? Siemers, E. R.
2009
13 4 p. 341-343
article
9 Imaging and biomarkers will be used for detection and monitoring progression of early Alzheimer’s disease Weiner, M. W.
2009
13 4 p. 332-333
article
10 Impact of food aid on food variety and dietary diversity of an elderly community in Sharpeville, South Africa Oldewage-Theron, W. H.
2009
13 4 p. 300-308
article
11 Interest of the new criteria for drug trials in AD Dubois, B.
2009
13 4 p. 356-357
article
12 Interpreting biomarker data in therapeutic trials Aisen, P. S.
2009
13 4 p. 337-338
article
13 Knowing the natural course of biomarkers in AD: Longitudinal MRI, CSF and PET data Flier, W. M. Van Der
2009
13 4 p. 353-355
article
14 Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: The Alzhemedtm (Tramiprosate) experience Saumier, D.
2009
13 4 p. 370-372
article
15 Metabolic response to a ketogenic breakfast in the healthy elderly Freemantle, E.
2009
13 4 p. 293-298
article
16 Molecular imaging markers in clinical trials in Alzheimer’s disease Nordberg, A.
2009
13 4 p. 346-347
article
17 Neuro-imaging: Structural and functional imaging Frisoni, G. B.
2009
13 4 p. 348-349
article
18 Sleep disorders and their impacts on healthy, dependent, and frail older adults Cochen, Valérie
2009
13 4 p. 322-329
article
19 Structural imaging markers for therapeutic trials in Alzheimer’s disease Fox, N. C.
2009
13 4 p. 350-352
article
20 The association of thyroid stimulating hormone levels with cognitive function and depressed mood: The Rancho Bernardo study Kritz-Silverstein, D.
2009
13 4 p. 317-321
article
21 The validity of biomarkers as surrogate endpoints in Alzheimer’s disease by means of the Quantitative Surrogate Validation Level of Evidence Scheme (QSVLES) Wied, C. C. Gispen-De
2009
13 4 p. 376-387
article
22 Unawareness of weight and height - the effect on self-reported prevalence of overweight in a population-based study Ramos, E.
2009
13 4 p. 310-314
article
23 Use of biomarkers in Alzheimer’s trials Vellas, B.
2009
13 4 p. 331
article
24 Use of biomarkers to select the target population for clinical trials in subjects with mild cognitive impairment Visser, P. J.
2009
13 4 p. 344-345
article
25 Use of CSF biomarkers in Alzheimer’s disease clinical trials Blennow, K.
2009
13 4 p. 358-361
article
26 What we have learned from the myriad trials Hendrix, S. B.
2009
13 4 p. 362-364
article
27 What we have learned from the xaliproden Sanofi-aventis trials Douillet, P.
2009
13 4 p. 365-366
article
                             27 results found
 
 Koninklijke Bibliotheek - National Library of the Netherlands